Company Overview
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.20.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +132.56% |
| 6 Months: | -3.93% |
| 3 Months: | +4.67% |
| 1 Month: | +1.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.82 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 28.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KYTX Kyverna Therapeutics, Inc. PHARMA | 8.07 | -2.76 | $499.08M | 0.00% | -65.99% | -87.24% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -11.45M | -13.30M | -16.28M | -29.36M | -33.44M | -38.77M | -47.41M | -44.41M | -38.73M | -41.37M |
| Net Income | -11.14M | -13.09M | -15.46M | -26.69M | -28.80M | -34.49M | -44.63M | -42.08M | -36.79M | -39.73M |
| Diluted EPS | -12.10 | -20.86 | -23.27 | -1.12 | -0.67 | -0.80 | -1.03 | -0.97 | -0.85 | -0.66 |
| R&D Expense | 8.71M | 10.40M | 13.64M | 22.48M | 27.32M | 29.19M | 37.43M | 35.82M | 30.46M | 30.07M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -62.41M | -142.60M | -169.83M |
| Net Income | -60.37M | -127.48M | -161.31M |
| Diluted EPS | -89.61 | -3.33 | -3.64 |
| R&D Expense | 49.92M | 112.47M | 133.72M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 75.19M | 304.64M | 293.83M |
| Total Equity | -74.00M | -13.14M | 266.59M | 232.28M |
| Cash & Equivalents | - | 34.65M | 96.62M | 124.09M |
| Total Liabilities | - | 26.02M | 38.06M | 61.55M |
| Current Liabilities | - | 19.86M | 33.76M | 36.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -52.41M | -114.25M | -153.71M |
| Investing Cash Flow | -8.79M | -160.90M | 40.02M |
| Financing Cash Flow | 58.12M | 337.11M | 141.17M |
| Capital Expenditure | -621.00K | -2.21M | -5.00K |
| Free Cash Flow | -53.03M | -116.45M | -153.72M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 459.4% | -47.8% | -69.4% |
| ROCE % | -112.8% | -52.6% | -66.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | 6.86% | 4.24M | $30.27M |
| 2 | Gilead Sciences Inc | 6.67% | 4.13M | $29.42M |
| 3 | Blackrock Inc. | 5.07% | 3.13M | $22.35M |
| 4 | Bain Capital Life Sciences Investors, LLC | 4.67% | 2.88M | $20.57M |
| 5 | AIGH Capital Management LLC | 4.52% | 2.80M | $19.93M |
| 6 | Deerfield Management Company, L.P | 3.23% | 2.00M | $14.26M |
| 7 | Vanguard Capital Management LLC | 3.07% | 1.90M | $13.53M |
| 8 | Price (T.Rowe) Associates Inc | 1.92% | 1.19M | $8.46M |
| 9 | Geode Capital Management, LLC | 1.70% | 1.05M | $7.48M |
| 10 | Insight Holdings Group, LLC | 1.60% | 989.05K | $7.05M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KYTX
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPbG44YV9rUk5zcXpqakVlYmF2ekd5UV8yYjhsSEI0enBHZnNZM3pqTXAwWVE1cklVbXU4cEl6Yzk5ZGZ6TDA3MVVhV3VuaFlITV91SldvSGZha21CQWF1MDlKRXQ5VUJ6Sk5GMGdNWU9SMVF0Y1BTOHNiYUxQaEluaEN3Y0xjZ3dkcFlHNH…
Technical Reactions to KYTX Trends in Macro Strategies - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPWjFJSEd1aXRJdV9tMTl2U0R3TDdEVlNCQUJFZ0FZeVJ5NzU2YXZ5Nm5qSjcweVlIckJjUkktR0IwR1BxNmxRWFl3VlQwcWtHbzBVaGt6bC1xZzEyNklKbEgyVGxHRm1FY1poU2ZFd2JKN1p1NHFmcjljRkQybnV5aWpJZ29qSEtpWERoaz…
Kyverna Therapeutics Sinks 13%: Here’s Why - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPU0c5dFdtRFd2QTFLQlBFME1DM0w4d3d0UWNwaDNMaFZHQXhvd0FtNXV5R0pyYWpzWWY0ZWlvVDUzMVc3aHdFOG5vaGtfcEszQlZoMkVmMDNkWldqN1VPSXcxTkF0Tl9KZ3VPMncxUE16NmZBVkNGeHducTBLUUdxbUoxNHNKcGZVeUhMS3…
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNYUx2cjh2VFI2WGFLbHlLcXU5SnNNQWFFSUFVc3REZS1GUEdnbWM1c0cyMWpORko0d04xYjc2R0JmSEktRVlJdjJ2NldkSmtKWnhkc0U1cG9vTExmM29yVU9Jd2d2OW1CVHpqcnl3U2lia1BxOHJLX1JsWHplb0cyeUh4eFBCclFpcjBpTT…
Kyverna adds legal chief as it prepares for commercialization - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOc2g3cVM3ZGo2b0pTYmVpRUEybUpUNzhYQng5S2pJYzUteWRuWEFvUWdtcGFFZXpKaWJYc2VpYWtpdlE3eTQ2ZnE0VGJtMk5rYzloaE5udnhfeWgyVXEzQjM1OF9UZnh5dzJSUGZMNm1MUkZwQTJ3d2ZLOTlYWWE2eFhlX1FzbWFhMjR5cE…
KYTX - Kyverna Therapeutics Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1COHd3OGVLeVIzTjQzTk5YcElzX3JTWTVSY1JVT2pzbkxZbzJOdlF1ZVRWaXRDcllCcmhDQ2UxalNsU0FLMWc?oc=5" target="_blank">KYTX - Kyverna Therapeutics Inc Stock Price and Quote</a> <fo…
KYTX — Frequently Asked Questions
What is the current share price of Kyverna Therapeutics, Inc. (KYTX)?
As of 2026-09-19 21:16 PDT, Kyverna Therapeutics, Inc. (KYTX) trades at $8.07 on NasdaqGS. Its 52-week range is $3.30 to $11.25.
What is the market capitalisation of KYTX?
Kyverna Therapeutics, Inc. (KYTX) has a market capitalisation of $499.08M on NasdaqGS.
What is the P/E ratio of KYTX?
KYTX trades at a trailing price-to-earnings (P/E) ratio of -2.76. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.65.
What is the return on equity (ROE) of KYTX?
KYTX has a return on equity (ROE) of -87.24%. Its return on capital employed (ROCE) is -65.99%.
Is KYTX a good stock to buy?
This page provides a data-driven analysis of Kyverna Therapeutics, Inc. (KYTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.